Specialty
Clinical Focus
Education
MBBS, Medical College of Bengal
Internship, Internal Medicine
Topiwala National Medical CollegeResidency, Pediatrics
BJM Hospital for ChildrenResidency, Pediatrics
Hospitals in South-East EnglandResidency, Gastroenterology
Royal Free Hospital Sch of MedicineFellowship, Pediatrics
University of London (King's College)Fellowship, Pediatrics
University of London (King's College)Fellowship, Pediatric Gastroenterology
University of London (King's College)Fellowship, Hepatology
University of London (King's College)
Biography
Dr. Kerkar's areas of interest are autoimmune hepatitis including de novo autoimmune hepatitis following transplantation, viral hepatitis, nonalcoholic fatty liver disease and investigating adherence to medical regimes in children.
Dr. Kerkar completed her undergraduate schooling and medical education in Calcutta, India. She was awarded The Children Nationwide Research Scholarship in 1996 by the Royal college of Physicians and completed two years of basic research training in Immunology at University College, London. She then completed the equivalent of board certification in pediatrics and pediatric Gastroenterology/Hepatology at King's College Hospital in London, England.
Among Dr. Kerkar's many society memberships are the American Association of the Study of Liver Disease, American Society of Transplant surgeons, International Pediatric Transplantation Society and North American society of Pediatric Gastroenterology, Hepatology and Nutrition.
Dr. Kerkar is the PI for studying 'Adefovir in children with chronic hepatitis B virus infection', 'Adherence to medications in children' and 'Newer immunosuppressive regimens in pediatric liver transplantation'. Her research efforts to date have mainly focused on autoimmune hepatitis. She is currently establishing protocols to study and manage children with nonalcoholic steatohepatitis (NASH) and chronic hepatitis B virus infection.
Research
PI for Newer Immunosuppressive regimens in pediatric liver transplantation
This will be a retrospective review of the charts to ascertain indications for starting additional immunosuppressive agents, assess outcome of the liver graft and recipient on the new regime and thus enable tailoring of immunosuppression in complicated patients.
Publications
Kerkar N, Hadzic N , Davies ET, Portmann B , Donaldson PT, Rela M , Heaton ND, Vergani D , Mieli-Vergani D . De-novo autoimmune hepatitis after liver transplantation. Lancet 1998 Feb; 351(9100): 409-13.
Kerkar N, Ma Y, Hussain M, Muratori L, Bianchi F, Mieli-Vergani G, Vergani D. A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of Liver Kidney Microsomal Antibody Type 1. Journal of Immunological Methods 1999; 223: 227-235.
Ma Y, Thomas MG, Okamoto M, Bogdanos DP, Nagl S, Kerkar N, Lopes AR, Muratori L, Lenzi M, Bianchi FB, Mieli-Vergani G, Vergani D. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. Journal of Immunology 2002; 169: 277-285.
Shemesh E , Shneider BL, Savitzky JK, Arnott L , Gondolesi GE, Krieger NR, Kerkar N, Magid MS, Stuber ML, Schmeidler J , Yehuda R , Emre S . Medication adherence in pediatric and adolescent liver transplant recipients. Pediatrics 2004 Apr; 113(4): 825-32.
Kerkar N. Non-alcoholic steatohepatitis in children. Pediatr Transplant 2004 Dec; 8(6): 613-8.
Kerkar N, Gold D , Thung SN, Shneider BL. Jaundice accompanied by giant cell hepatitis and eosinophilia in childhood. Semin Liver Dis 2004 Feb; 24(1): 107-11.
Kerkar N. Evaluating the AIH scoring system. J Pediatr Gastroenterol Nutr 2005 Jul; 41(1): 137-8.
Kerkar N. Hepatitis B in children: Complexities in management. Pediatr Transplant 2005 Oct; 9(5): 685-91.
Kerkar N, Dugan C , Rumbo C , Morotti RA, Shneider BL, Emre S . Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005 May; 5(5): 1085-9.
Kerkar N, Shneider BL. Evolving approaches to the treatment of chronic hepatitis B virus infection in children [editorial]. J Clin Gastroenterol 2005 Jan; 39(1): 7-9.
Clinical Trials
Industry Relationships
Physicians and scientists on the faculty of Mount Sinai School of Medicine often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Kerkar during 2011 and/or 2012. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Gilead Sciences, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://www.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
5 East 98th Street
12th Floor
New York, NY 10029
- Monday 9:00am - 5:00pm
- Tuesday 9:00am - 5:00pm
- Wednesday 9:00am - 5:00pm
- Thursday 9:00am - 5:00pm
- Friday 9:00am - 5:00pm
- Spanish
- Indian (Hindi)
- Aetna
- Blue Cross/ Blue Shield
- Healthnet-Empire BCBS
- Medicaid
- Master Card
- Visa
- American Express
- Personal Check
- Cash